need more than the quarterly, page-22

On the 02/08/05, they stated to the ASX in regards to their cash flow problems and whether they are an ongoing entity by staing outright that Ropren is expected to be added to the Russina Pharmacopeia in 2006.

It's not a good look - its been going on for some time - but its crunch time for her in what remains in 08/09 or else a sig further placement may need to take place - which has been flagged as perhaps bringing the shares on offer to 300m, perhaps IMO via a "pharma network" - whatever that means.

Distribution and marketing is what is needed perhaps, as long as you believe in the efficacy which is IMO debateable.

The tide will go out soon enough which will show whether they are swimming naked or not.

The company intrigues me, along with IMO why some astute investors here and elsewhere have been bitten by the blue sky.